Meningitis and invasive meningococcal infections

• 2023/04 - Opinion and update on meningococcal vaccination (Pdf, 855 Kb)

Free vaccines will not be available until 1 January 2024, as of which time orders can be placed with the Health Directorate.

• 2018/11 - Opinion (Pdf, 488 Kb) on meningococcal group B vaccination
  
  In 2018, the Superior Council of Infectious Diseases (Conseil supérieur des maladies infectieuses - CSMI) decided not to recommend generalising meningococcal group B vaccination, and specified the at-risk groups and the vaccination schedule that would apply in case of vaccination.
  
  
• 2018/05 - Meningococcal group C vaccination (Pdf, 172 Kb): CSMI's updated recommendations
  
  At its meeting on 7 May 2018, the CSMI decided to recommend the introduction of a second dose of meningococcal group C (MenC) vaccination during adolescence, in order to provide adolescents and young adults with adequate protection against MenC, and mitigate the risk of it spreading to the general population.
  
  
• 2016/04 - Opinion (Pdf, 228 Kb) on meningococcal group B vaccination
  
  At its meeting on 19 April 2016, the CSMI decided not to recommend generalising meningococcal group B vaccination, for the time being.
  
  
• 2015/03 - Post-Exposure Prophylaxis (Pdf, 479 Kb) (PEP) in the presence of one or several cases of invasive meningococcal (Neisseria meningitis) infection
  
  The purpose of this communication is to describe the prophylactic measures that should be implemented in the event of invasive meningococcal infection. In the main, these measures are chemoprophylactic measures entailing the administration of antibiotics, and vaccination, in certain cases.
  
  
• 2006/06 - Recommendations (Pdf, 350 Kb) on meningococcal group C vaccination
  
  Owing to the increase in the number of cases of meningococcal group C infections, the Superior Council of Infectious Diseases (CSMI) – formerly the Conseil supérieur d’hygiène – recommends vaccinating all children aged one to 19 years. However, the CSMI recommends against routine vaccination of infants under the age of 12 months. In addition to these recommendations, this document contains information on the following topics: the extent of the problem, chemoprophylaxis, the vaccine and its effectiveness, its side effects, and its vaccination schedule.